Newly described human antibody prevents malaria in mice

March 19, 2018, NIH/National Institute of Allergy and Infectious Diseases
The malaria sporozoites, the infectious form of the malaria parasite. Credit: NIAID

Scientists have discovered a human antibody that protected mice from infection with the deadliest malaria parasite, Plasmodium falciparum. The research findings provide the basis for future testing in humans to determine if the antibody can provide short-term protection against malaria, and also may aid in vaccine design. Investigators at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, led the research with colleagues at the Fred Hutchinson Cancer Research Center in Seattle. Currently, there is no highly effective, long-lasting vaccine to prevent malaria, a mosquito-spread disease that causes some 430,000 deaths each year, primarily among young children in sub-Saharan Africa.

The research team isolated the antibody, called CIS43, from the blood of a volunteer who had received an experimental vaccine made from whole, weakened parasites (PfSPZ Vaccine-Sanaria). The volunteer was later exposed to infectious malaria-carrying mosquitoes under carefully controlled conditions and did not become infected. In two different models of malaria in mice, CIS43 was highly effective at preventing malaria infection. If confirmed through additional studies in people, CIS43 could be developed as a prophylactic measure to prevent infection for several months after administration, the researchers say. Such a prophylactic antibody could be useful for tourists, health care workers, military personnel or others who travel to areas where malaria is common. Moreover, if the antibody prevented malaria infection for up to six months, it might be combined with antimalarial drugs and be deployed as part of mass drug administration efforts that potentially could eliminate the disease in malaria-endemic regions.

Detailed examination of CIS43 revealed that it works by binding to a specific portion (epitope) of a key parasite surface protein. This epitope occurs only once along the length of the surface protein. In addition, the CIS43-binding epitope is conserved across 99.8 percent of all known strains of P. falciparum, making it an attractive target for next-generation experimental malaria vaccines designed to elicit production of this neutralizing antibody.

Researchers at the NIAID Vaccine Research Center are planning to assess the safety and protective efficacy of the newly described CIS43 antibody next year in controlled human challenge trials.

Additional collaborators on the study included scientists at the Johns Hopkins Bloomberg School of Public Health in Baltimore, the Seattle Biomedical Research Institute and Sanaria Inc., Rockville, Maryland.

The study is published in Nature Medicine.

Explore further: Modified experimental vaccine protects monkeys from deadly malaria

More information: A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite, Nature Medicine, nature.com/articles/doi:10.1038/nm.4512

Related Stories

Modified experimental vaccine protects monkeys from deadly malaria

May 22, 2017
Researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, modified an experimental malaria vaccine and showed that it completely protected four of eight ...

Experimental vaccine protects against multiple malaria strains

February 20, 2017
An experimental malaria vaccine protected healthy subjects from infection with a malaria strain different from that contained in the vaccine, according to a study published today in the Proceedings of the National Academy ...

Human antibodies undermine parasite sex

February 8, 2018
Some people develop an immune response following a malaria infection that stops them from infecting other mosquitoes. The antibodies that these people produce are ingested by the mosquito and destroy the malaria parasite ...

New study finds that malaria vaccine protects adults for up to a year

May 9, 2016
Malaria infects hundreds of millions of people every year, and kills more than half a million, most of them under the age of 5 years. There is no vaccine.

Discovery of key molecules involved in severe malaria – new target for malaria vaccine

December 4, 2017
Malaria is one of three major infectious diseases affecting approximately 300 million people every year, accounting for about 500,000 deaths, but effective vaccine development has not been successful. Among malaria parasites ...

Vaccine made from complex of two malaria proteins protects mice from lethal infection

June 23, 2014
An experimental vaccine designed to spur production of antibodies against a key malaria parasite protein, AMA1, was developed more than decade ago by scientists from the National Institute of Allergy and Infectious Diseases ...

Recommended for you

Researchers make essential imaging tests safer for people at risk of acute kidney injury

October 15, 2018
Every year, millions of people undergo medical tests and procedures, such as coronary angiography, which use intravascular contrast dyes. "For the majority of patients, these are safe and necessary procedures. However, about ...

Medical marijuana might help MS patients, but uncertainty remains

October 13, 2018
Medical products derived from marijuana might have a mild benefit in treating symptoms of multiple sclerosis, based on reports from patients.

Do not give decongestants to young children for common cold symptoms, say experts

October 11, 2018
Decongestants should not be given to children under 6—and given with caution in children under 12—as there is no evidence that they alleviate symptoms such as a blocked or runny nose, and their safety is unclear, say ...

New techniques can detect Lyme disease weeks before current tests

October 11, 2018
Researchers have developed techniques to detect Lyme disease bacteria weeks sooner than current tests, allowing patients to start treatment earlier.

Pneumonia-causing bacteria can be spread by nose picking and rubbing

October 11, 2018
Pneumonia-causing bacteria can be spread through picking and rubbing the nose, according to new research published in the European Respiratory Journal.

Plant compound found to have therapeutic effect on complications from snakebites

October 11, 2018
Rutin, a flavonoid, may complement antivenom as an effective co-treatment for envenoming from Bothrops jaraca.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.